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Abstract 
Objectives: Better understanding dyspepsia in Parkinson’s disease 
(PD) in order to improve  patients quality of life. 
Methods: 27 patients (17 men,10 women, mean age=68,11± 12,62 years) 
diagnosed with PD (Hoehn-Yars scale), treated with  levodopa or dopamine 
agonists, with gastrointestinal autonomic disorders and disturbances of 
gastric motility assessed by ultrasound approach  undertook a trial consisting 
of a treatment with Trimebutine 300 mg/day for 3 months. We have assessed  
digestive severity symptoms scores before and after therapy: no 
symptoms=0, mild=1, medium=2, severe=3,  comparing also to gastric 
motility curves. 
Results: Before therapy 15 patients showed delayed of the gastric emptying 
(55,56%), 7 normal motility (25,92%) and 5 patients rapid  emptying 
(18,51%).Symptoms severity scores before therapy were: 8 patients 
(29,52%) mild ,14 patients (51,85%) medium and 5 patients 
(18,51%).severe. Mean dyspepsia severity index in patients with gastric 
motility disorders  before therapy was 2,20±0,52.After therapy the same 
index decreased to 1,50±0,69(p=0,0009).Gastric motility curves showed an 
improving after therapy more important in those with delaying emptying 
varying with 23,45%±14,03 versus 15%±5,87% in patients with rapid 
emptying (either p<0,001). 
Conclusions An important range of patients with PD, with nausea and 
vomiting  presented gastric motility disorders (74,07%), most of them having 
delay of the emptying and  a satisfactory response  to the treatment with 
Trimebutine  with improving of symptom severity index  and  also gastric 
motility.  
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Introduction 
The autonomic problems of Parkinson's disease as non-motor features 
include gastrointestinal (GI) and  urinary dysfunction, and a variety of other 
problems, such as sweating, sexual dysfunction, drooling   that are  in fact, 
other burden to deal with.  
GI dysfunction is often seen, patients complaining of disturbances of 
intestinal habit with constipation, bloating, flatulence and abdominal pain. 
Some studies reported a high prevalence of constipation (58%) among 
patients with PD [Magerfurth 2005, Cersosimo 2008]. But many of 
dyspeptic symptoms are also related to troubles of the gastric motility 
probably due to neurodegenerative processes that also involved digestive 
system, specific dopaminergic medication and many other causes that are not 
yet fully understood. There are studies  showing a prevalence of delaying of 
gastric emptying up to 70% of patients with PD [Ceravolo 2010 ]. 
Considering some similarities between FD and GI involvement in PD with 
autonomic disorders, we decided to  manage the dyspeptic troubles of 
patients with PD with an agent used for his prokinetic abilities, like 
Trimebutine. Trimebutine acts on the gastrointestinal tract via (1) an agonist 
effect on peripheral mu, kappa and delta opiate receptors and (2)  by 
releasing of gastrointestinal peptides such as motilin and modulation of the 
release of other peptides, including vasoactive intestinal peptide, gastrin and 
glucagon. Trimebutine accelerates gastric emptying, induces premature 
phase III of the migrating motor complex in the intestine and modulates the 
contractile activity of the colon[Hyama et all, 2007]. 
Patients and methods 
Study design : open label clinical study in a cohort of 27 patients (17 
men,10 women, mean age=68,11± 12,62 years), diagnosed with PD 
according to Hoehn-Yars scale [Ramaker, 2002].  
Patients showed at enrolment associated  non-motor GI dyspeptic 
symptoms like nausea, vomiting and bloating and the neurological disease 
was treated with  levodopa or dopamine agonists at the Neurological Clinic, 
County Hospital Timisoara. Before joining this study they were also 
thoroughly gastroenterological evaluated. Lab tests and endoscopic digestive 
work-up were performed.We ruled out  gastro-intestinal and gallbladder 
conditions, infection with Helicobacter Pylori, treatment with NSAID or 
aspirin. Diabetes mellitus, thyroid and collagen disorders, hepatic and renal 
failure were also criteria of unselection. Assessment of gastric motility was 
based on ultrasound approach with study of the emptying of the stomach 
[Bolondi,1985].Patients who showed disorders of the gastric emptying 
received Trimebutine. The study was aproved by the local ethical comitee 
and patients and their families provided written informed consent. 
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GASTRIC ANTRAL EMPTYING IN 
CONTROLS
0
50
100
150
1 2 3 4 5 6 7
TIME FROM 0' TO 90' EVERY 15'
PE
R
C
EN
TA
G
E 
O
F 
A
N
TR
A
L 
A
R
EA
Ultrasound examination of the stomach  with assessment of antral 
emptying  was based on the measurement of antral area in a sagittal section 
of the gastric wall through the aortic and mesenteric artery plane. We  
calculated  maximal antral distension  (percentage of antral area  distension 
after finishing the  fluid-solid test meal), half time of gastric emptying (T½). 
Measurements were made  from time 0 every 15 minutes until 90 minutes 
using a highly performance ultrasound device( General Electric Logiq 5 
Expert, convex array transductor 3,5-5 Mhz).Ultrasound  measurements were 
performed in patients and 10 controls ( mean age=60,4±5,31 years) and 
gastric antral motility curves were drawn. 
Patients received a treatment with Trimebutine 300 mg/day, for 3 
months; no  cases of drop out were recorded. After finishing the treatment 
we repeated the ultrasound examination of gastric motility. We have 
assessed  digestive severity symptoms scores before and after therapy (no 
symptoms =0, mild=1, medium=2, severe=3) comparing also to gastric 
motility curves.  
 
 
 
 
 
 
 
 
 
Figure 1. Antral motility in controls ( mean values percentage T½) and ultrasound feature 
 
Demographic patients chart showed that they lived in urban or 
proximity urban  locations with very good access to medical attention. 
Statistical analysis  was  made using GraphPad software with the 
panel for continous data,  with descriptive statitistics and calculation of mean 
values and standard deviation, unpaired t test, statistical distribution and 
interpreting p values with CI= 95%, for setting the statistic significance  and 
nonparametric Spearman  correlation with calculation of r coefficient in 
order to quantify the magnitude and direction of correlation. 
Results 
Our patients baseline neurological data, as  revealed in the figure 
below, showed that at the time of starting this study, they had various PD 
disease staging, according to Hoehn-Yars scale : with 1 point 1 patient 
(3,70%), with 1,5 points 1 patient (3,70%), with 2 points 7 patients 
(25,92%), with 2,5 points 1 patient (3,70%), with 3 points 14 patients 
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(51,85%), with 4 points 2 patients (7,40%), and with 5 points 1 patient ( 
3,70%). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Staging of patients with PD at the start of the study 
 
As depicted in the figure 3, before therapy, on ultrasound 
examination, the majority of patients (15 patients= 55,56%) showed delay of 
the gastric emptying, a quarter of patients ( 7 patients= 25,92%), displayed  
normal motility and a small percentage (5 patients = 18,51%), had a rapid 
gastric  emptying. 
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Figure 3. Ultrasound results  of antral motility 
 
Analysis of symptoms severity scores before therapy are shown in the 
figure below. In 8 patients (29,52%) we‘ve found  mild  symptoms, in 14 
patients (51,85%)  medium severity symptoms and  in 5 patients (18,51%) 
severe complaints. 
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Figure 4. Symptoms severity 
 
No significant correlation between severity scoring of PD and 
dyspepsia was set (  r=0,081). 
           Table with dyspepsia and antral motility related to therapy 
 BEFORE 
THERAPY 
AFTER 
THERAPY 
P 
Mean dyspepsia 
index in patients with motility disorders 
2,20±0,52. 1,50±0,69 p=0,0009 
T½ antral percentage in patients with delaying 
emptying 
24,45±14,039 44,05±11,95 P=0,0001 
T½ antral percentage in patients with rapid 
emptying 
68,83±3,82 55,80±3,19 P=0,0002 
 
As shown in the table above mean dyspepsia severity index in 
patients with gastric motility disorders  before therapy was 2,20±0,52. After 
therapy the same index decreased to 1,50±0,69, p=0,0009, being highly  
statistical significant. 
 
 
 
 
 
 
 
 
 
 
Figure 5. Delayed antral emptying and therapeutic respone 
 
 
 
 
THERAPY RESPONSE IN PATIENTS WITH DELAYED GASTRIC EMPTYING
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THERAPY RESPONSE IN PATIENTS WITH RAPID GASTRIC EMPTYING
0
10
20
30
40
50
60
70
80
1 2 3 4 5 6
T 1/2 
PERCENTAGE 
OF GASTRIC 
EMPTYING
RAPID GASTRIC EMPTYING
0
50
100
150
1 2 3 4 5 6 7
MINUTES FROM 0 TO 90
PE
R
C
EN
TA
G
E 
O
F 
A
N
TR
A
L 
EV
A
C
U
A
TI
O
N
 
 
 
 
 
 
 
 
 
Figure 6. Rapid antral emptying and therapeutic response 
 
Gastric motility curves showed an improvement after therapy with 
23,45%±14,03% (p<0,0001) in those with delaying emptying; in patients 
with rapid emptying of the stomach we recorded an improvement  with 
15%±5,87%  ( p<0,001). 
Discussions 
Non-motor symptoms in patients with PD are very frequently 
reported from early stages of disease. In a two years followed-up study in 
patients with  previously untreated PD, the incidence of non-motor 
complaints was very high. In fact  nearly all patients ( 97,8%) reported at 
enrollment at least one symptom of a nonmotor issue[Erro at al, 2013]. 
There are studies that advocated the fact that:”pathology of 
Parkinson's disease (PD) extends far beyond the nigrostriatal system and 
results in non-motor symptoms coexisting with motor symptoms”[ Rupam, 
2010]. 
As stated above these non-motor symptoms are not related to the 
disease extent, by the contrary they are present quite early in the evolution  
of PD and sometimes even precede motor symptoms by years in patients that 
are practically not diagnosed with PD. It’s quite clear that they cause 
significant morbidity and lower the quality of life in patients that are already 
suffering [Lim and Lang, 2010]. 
It was also reported that they are often under recognised by health 
professionals [Parsons et al. 2006].  
The effect of various therapeutic modalities on non-motor symptoms 
is still unclear.There are some studies about correction of dysphagia and 
constipation showing different modalities of treatment[Cucci 2008, Parsons 
2006, Tateno 2011, Rupam 2012]. However there is no recording data 
regarding gastric dismotility treatment with Trimebutine in PD.  
Trimebutine is a therapeutic agent prescribed mostly in patients with 
functional dyspepsia(FD), irritable bowell syndrome, chronic constipation 
and other functional gastro-intestinal disorders due to its effect on the 
European Scientific Journal   August 2013  edition vol.9, No.24  ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
98 
regulation of the motility of the  digestive  system [Schmolson and Chang, 
2011]. 
In a metaanalysis published in J Gastroenterology and Hepatology in 
2007 it was clearly highlighted the significant treatment benefit in favor of 
prokinetic agents, including Trimebutine in patients with FD [Hyiama et al, 
2007]. Other studies that analysed FD and its treatment also reported good 
results in treatment with prokinetic, Trimebutine being one of them 
[Schmolson and Chang, 2011]. 
From what we know this is the first study with Trimebutine in 
patients with PD and non-motor GI disorders. Our data after finishing the  
first  session of treatment with Trimebutine  showed a  good toleration,  with 
no report of side-effects or drop-out cases. The treatment response  was 
satisfactory both in terms of gastric motility management and also in 
mitigating the dyspeptic syndrome.  
However, there was a better outcome in patients with delaying of the 
gastric emptying, motility curves showing an improvement with  
23,45%±14,03% vs. 15%±5,87% (p<0,0001 high significant), in those with 
rapid gastric emptying.  
Further observation should be taken in order to see  how much GI 
responsivity to this treatment will be maintained in a long term therapy. 
Conclusion 
An important range of patients with PD having dyspepsia exhibited at 
ultrasound examination gastric motility disorders (74,07%), most of them 
having delaying of the gastric emptying. 
We recorded a satisfactory response  to the treatment with Trimebutine, with 
improving of symptom severity index  and  gastric motility both ways, but  
better in patients with delaying of the gastric emptying.  
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